On January 29, 2025, the Federal Circuit issued paired decisions addressing Samsung Bioepis’s (“SB”) and Formycon AG’s (“Formycon”) appeals of preliminary injunctions entered in ongoing aflibercept biosimilar litigations with...more
1/31/2025
/ Abbreviated New Drug Application (ANDA) ,
Appeals ,
Biosimilars ,
Food and Drug Administration (FDA) ,
Foreign Corporations ,
Generic Drugs ,
Hatch-Waxman ,
Life Sciences ,
Marketing ,
Patent Litigation ,
Personal Jurisdiction ,
Pharmaceutical Patents ,
Preliminary Injunctions
On October 15, 2021, the U.S. Food and Drug Administration (“FDA”) approved Boehringer Ingelheim’s Cyltezo® (adalimumab-adbm), the first interchangeable biosimilar to AbbVie’s blockbuster immunosuppressant Humira®...more